fbpx
September 24, 2021

FDA Okays Evolocumab Add-On for FH in Children Aged 10 and Up FDA Okays Evolocumab Add-On for FH in Children Aged 10 and Up

The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other […]
September 24, 2021

TVT Registry Low-risk Bicuspid TAVR 1-Year Results Hit Print TVT Registry Low-risk Bicuspid TAVR 1-Year Results Hit Print

Transcatheter aortic valve replacement (TAVR) provides comparable stroke and mortality rates out to 1 year in low-risk patients with bicuspid and tricuspid aortic stenosis, registry data suggest. […]
September 23, 2021

Physical Activity Paradoxically Tied to Higher Coronary Calcium Physical Activity Paradoxically Tied to Higher Coronary Calcium

Physical activity, long recommended by health experts to reduce risk for obesity, heart disease, type 2 diabetes, high blood pressure, hypercholesterolemia, and other cardiovascular disease risk factors, […]
September 22, 2021

Empagliflozin’s HFpEF Efficacy Catalyzes Redefinition of HF Empagliflozin’s HFpEF Efficacy Catalyzes Redefinition of HF

Groundbreaking results from the EMPEROR-Preserved trial did more than establish for the first time that a drug, empagliflozin, has clearly proven efficacy for treating patients with […]
September 22, 2021

STEMI Latecomers Still Benefit From Coronary Revascularization STEMI Latecomers Still Benefit From Coronary Revascularization

Patients with ST-segment elevation myocardial infarction (STEMI) who delay seeking care for more than 12 hours still derive significant benefit from coronary revascularization of the infarct […]
September 22, 2021

Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure

NEW YORK (Reuters Health) – Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say. […]
September 21, 2021

Cardiogenic Shock Teams Again Tied to Lower Mortality Cardiogenic Shock Teams Again Tied to Lower Mortality

A large multicenter study provides further evidence supporting the rationale for multidisciplinary teams for cardiogenic shock, one of the most lethal diseases in cardiovascular medicine. The […]
September 20, 2021

FDA Approves Abbott’s Portico Valve for TAVR FDA Approves Abbott’s Portico Valve for TAVR

The US Food and Drug Administration has approved the Portico with FlexNav (Abbott) transcatheter aortic valve replacement (TAVR) system for patients with “symptomatic, severe aortic stenosis […]
September 17, 2021

AHA Reverses Course on Hybrid 2021 Sessions for All-Virtual Event AHA Reverses Course on Hybrid 2021 Sessions for All-Virtual Event

The American Heart Association (AHA) has reversed its earlier decision to offer a hybrid format for the 2021 Scientific Sessions in Boston in November, going instead […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0